Fig. 7

Pharmacokinetic analysis of iluzanebart in hTREM2-CV mice. Terminal iluzanebart brain concentrations and corresponding fold exposures over iluzanebart in vitro sCSF1R EC₅₀ and sTREM2 IC₅₀ pharmacologically align with on-target TREM2 agonism. Values are reported as mean ± standard deviation, n = 4–6 mice per group. A hTREM2-CV mice were dosed intraperitoneally with a single dose of iluzanebart, and brain and plasma concentrations were measured 24 h later. A minimal dose of 10 mg/kg was shown to achieve brain levels equal to or higher than the pSYK EC50 in iPSC derived microglia. B Terminal iluzanebart brain concentrations and corresponding fold exposures over iluzanebart in vitro sCSF1R EC₅₀ and sTREM2 IC₅₀. Iluzanebart Plasma concentrations of iluzanebart in the 100 and 200 mg/kg dose groups was above the limit of quantitation and was therefore excluded